Blog

Joanna Shields speaks at the Global Partnership on Artificial Intelligence

At the Global Partnership on Artificial Intelligence (GPAI) summit, Benevolent AI CEO Joanna Shields shared her belief that humanity should be at the heart of AI.

Last week international AI experts across industry, civil society, academia and government from over 60 countries came together virtually for the first plenary of the Global Partnership on Artificial Intelligence (GPAI) in Montreal. At the end of an immensely challenging year, the members reflected on the power AI has to fuel discoveries, empower scientists and shape the world when used responsibly.

Our CEO Joanna Shields, proudly represented the United Kingdom as the newly elected Chair of the Steering Committee and the Multistakeholder Group. She shared the stage with Prime Minister Justin Trudeau and the President of France, Emmanuel Macron, who co-led the effort to establish GPAI through their 2018 and 2019 G7 presidencies. The two world leaders addressed the summit with their vision to guide the responsible development and use of AI globally, with Trudeau describing how ‘we must not forget that positive change doesn’t happen by itself, we have to choose it’.

Joanna opened the final plenary of the day with a speech that echoed these words. She focused on the power human ingenuity and AI has to propel us forward, and ultimately benefit all. She described how AI is at its most powerful when it is the result of a fusion between humanity and technology, as well as the need for purposeful technology which reflects the values of our society.

She drew on her learnings from the first digital revolution and the necessity to ensure that frameworks and standards are embedded in our development of new AI. The purpose of GPAI is to provide these guiding principles because, in her words, ‘AI is a powerful force that we cannot afford to underestimate’.


More Posts

You Might Also Like

News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020